Traders Sell Thermo Fisher Scientific (TMO) on Strength (TMO)

Investors sold shares of Thermo Fisher Scientific Inc. (NYSE:TMO) on strength during trading hours on Wednesday. $29.67 million flowed into the stock on the tick-up and $44.64 million flowed out of the stock on the tick-down, for a money net flow of $14.97 million out of the stock. Of all equities tracked, Thermo Fisher Scientific had the 0th highest net out-flow for the day. Thermo Fisher Scientific traded up $0.83 for the day and closed at $191.17

TMO has been the topic of a number of recent research reports. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 target price on the stock in a report on Thursday, September 7th. Morgan Stanley reiterated an “overweight” rating and issued a $220.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. Cowen reiterated an “outperform” rating and issued a $220.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. Leerink Swann reiterated a “buy” rating on shares of Thermo Fisher Scientific in a report on Monday, October 30th. Finally, Deutsche Bank set a $226.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Thursday, October 26th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $205.21.

The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. The firm has a market cap of $76,658.29, a P/E ratio of 32.46, a price-to-earnings-growth ratio of 1.75 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The business had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $5.03 billion. During the same period last year, the business earned $2.03 EPS. The business’s revenue was up 13.9% on a year-over-year basis. sell-side analysts expect that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.31%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is 10.19%.

In other news, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, December 15th. The stock was sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the sale, the chief executive officer now directly owns 302,577 shares in the company, valued at approximately $58,016,113.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.49% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Atlantic Trust Group LLC raised its stake in shares of Thermo Fisher Scientific by 25.6% during the 3rd quarter. Atlantic Trust Group LLC now owns 710,772 shares of the medical research company’s stock worth $134,480,000 after purchasing an additional 144,924 shares during the period. AustralianSuper Pty Ltd raised its stake in shares of Thermo Fisher Scientific by 73.6% during the 3rd quarter. AustralianSuper Pty Ltd now owns 689,898 shares of the medical research company’s stock worth $130,529,000 after purchasing an additional 292,398 shares during the period. Parametric Portfolio Associates LLC increased its holdings in Thermo Fisher Scientific by 2.8% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 910,403 shares of the medical research company’s stock worth $172,248,000 after acquiring an additional 24,467 shares during the last quarter. AXA increased its holdings in Thermo Fisher Scientific by 9.2% in the 3rd quarter. AXA now owns 772,234 shares of the medical research company’s stock worth $146,107,000 after acquiring an additional 65,083 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC purchased a new stake in Thermo Fisher Scientific in the 3rd quarter worth about $1,634,000. Institutional investors own 86.22% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Traders Sell Thermo Fisher Scientific (TMO) on Strength (TMO)” was first posted by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://weekherald.com/2017/12/29/traders-sell-thermo-fisher-scientific-tmo-on-strength-tmo.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply